South Korean venture Curocell has filed for domestic regulatory approval of its next generation CD19-targeting drug Rimqarto (anbalcabtagene autoleucel or anbal-cel) for relapsed or refractory large B-cell lymphoma, taking a big step towards the possible launch of what would be the country’s first homegrown CAR-T therapy.
Korea’s First Homegrown CAR-T Therapy On Horizon
Curocell Files For Approval In LBCL
Rimqarto is poised to become the first homegrown South Korean CAR-T therapy to gain domestic approval and looks set to provide new local competition to Kymriah.
